Kranke Peter, Eberhart Leopold H, Roewer Norbert, Tramèr Martin R
Department of Anesthesiology, University of Würzburg, Germany.
Anesth Analg. 2002 Feb;94(2):453-60, table of contents. doi: 10.1097/00000539-200202000-00043.
Shivering is a frequent complication in the postoperative period. The relative efficacy of interventions that are used for the treatment of postoperative shivering is not well understood. We performed a systematic search (MEDLINE, EMBASE, Cochrane Library, hand searching, all languages, to August, 2000) for full reports of randomized comparisons of any pharmacological antishivering intervention (active) with placebo (control) in the postoperative period. Dichotomous data on absence of further shivering after treatment and adverse effects were extracted from original reports. Relative risk (RR) and number-needed-to-treat (NNT) were calculated with 95% confidence interval (CI) using a fixed effect model. Data from 20 trials (944 adults received an active intervention, 413 were controls) were analyzed. Antishivering efficacy depended on the active regimen and the length of follow-up. Efficacy with meperidine 25 mg, clonidine 150 microg, ketanserin 10 mg, and doxapram 100 mg was reported in at least three trials; all were significantly more effective than control. After 1 min, the NNT of meperidine 25 mg for no further shivering compared with placebo was 2.7 (RR, 6.8; 95% CI, 2.5-18.5). After 5 min, the NNT of meperidine 25 mg was 1.3 (RR, 9.6; 95% CI, 5.7-16), the NNT of clonidine 150 microg was 1.3 (RR, 6.8; 95% CI, 3.3-14.2), the NNT of doxapram 100 mg was 1.7 (RR 4.0; 95% CI, 2.4-6.5), and the NNT of ketanserin 10 mg was 2.3 (RR 3.1; 95% CI, 1.9-5.1). After 10 min, the NNT of meperidine 25 mg was 1.5 (RR 4.0; 95% CI, 2.5-6.2). After 15 min, the NNT of ketanserin 10 mg was 3.3 (RR 1.5; 95% CI, 1.2-1.9). Long-term outcome data were lacking. There were not enough data for alfentanil, fentanyl, morphine, nalbuphine, lidocaine, magnesium, metamizol, methylphenidate, nefopam, pentazocine, and tramadol to draw meaningful conclusions. Reporting of adverse drug reactions was sparse. Fewer than two shivering patients need to be treated with meperidine 25 mg, clonidine 150 microg, or doxapram 100 mg for one to stop shivering within 5 min who would have continued to shiver had they all received a placebo.
Less than two shivering patients need to be treated with meperidine 25 mg, clonidine 150 microg, or doxapram 100 mg for one to stop shivering within 5 min who would have continued to shiver had they all received a placebo.
寒战是术后常见的并发症。用于治疗术后寒战的干预措施的相对疗效尚未得到充分了解。我们进行了一项系统检索(检索MEDLINE、EMBASE、Cochrane图书馆,并进行手工检索,涵盖所有语言,截至2000年8月),以查找有关术后任何药理学抗寒战干预措施(活性药物)与安慰剂(对照)随机比较的完整报告。从原始报告中提取治疗后无进一步寒战的二分数据及不良反应。使用固定效应模型计算相对风险(RR)和需治疗人数(NNT),并给出95%置信区间(CI)。对20项试验的数据(944名成年人接受活性干预,413名作为对照)进行了分析。抗寒战疗效取决于活性治疗方案及随访时间。至少三项试验报告了哌替啶25mg、可乐定150μg、酮色林10mg和多沙普仑100mg的疗效;所有这些药物均比对照显著有效。1分钟后,与安慰剂相比,哌替啶25mg用于无进一步寒战的NNT为2.7(RR,6.8;95%CI,2.5 - 18.5)。5分钟后,哌替啶25mg的NNT为1.3(RR,9.6;95%CI,5.7 - 16),可乐定150μg的NNT为1.3(RR,6.8;95%CI,3.3 - 14.2),多沙普仑100mg的NNT为1.7(RR 4.0;95%CI,2.4 - 6.5),酮色林10mg的NNT为2.3(RR 3.1;95%CI,1.9 - 5.1)。10分钟后,哌替啶25mg的NNT为1.5(RR 4.0;95%CI,2.5 - 6.2)。15分钟后,酮色林10mg的NNT为3.3(RR 1.5;95%CI,1.2 - 1.9)。缺乏长期结局数据。关于阿芬太尼、芬太尼、吗啡、纳布啡、利多卡因、镁、安乃近、哌醋甲酯、奈福泮、喷他佐辛和曲马多的数据不足,无法得出有意义的结论。药物不良反应的报告较少。对于少于两名寒战患者,使用哌替啶25mg、可乐定150μg或多沙普仑100mg治疗,可使其中一人在5分钟内停止寒战,而如果他们都接受安慰剂,则会继续寒战。
对于少于两名寒战患者,使用哌替啶25mg、可乐定150μg或多沙普仑100mg治疗,可使其中一人在5分钟内停止寒战,而如果他们都接受安慰剂,则会继续寒战。